Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$103.8B
2,396M shares
52-week range
$40.89 – $52.68
13% from low
Exchange
NASDAQ
ADRC
P/S (TTM)
2.1
EV / FCF (TTM)
10.1
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest-revenue product, Dupixent, accounts for over 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.
www.sanofi.comNo one on the platform currently holds SNY.
No tracked institution reports a position in SNY as of their last filing.
| Ex-date | Per share | Pay date |
|---|---|---|
| 2026-05-04 | $2.4190 | 2026-06-03 |
| 2025-05-09 | $2.1953 | 2025-06-12 |
| 2024-05-09 | $2.0369 | 2024-06-06 |
No one on the platform has traded SNY yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 10.1% | 8.4% | 8.3% | — | — | — |
| Rev. Growth % | 5.5% | 4.6% | ||||
| Profit Margin % | 16.7% | 15.8% | 16.8% | |||
| Free Cash Flow Margin % | 21.7% | 19.0% | 16.7% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is +5.5% on the P/E track.
At today's price, your expected annual return is +10.6% on the P/E track.
At today's price, your expected annual return is +15.2% on the P/E track.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $47.7B | +5.7% | $4.18 | $4.11–$4.26 | 10.2× | 5 |
| 2027 | $50.7B | +6.3% | $4.47 | $3.93–$4.69 | 9.5× | 5 |
| 2028 | $53.3B | +5.2% | $4.90 | $4.61–$5.18 | 8.6× | 2 |
| 2029 | $55.6B | +4.3% | $5.43 | $5.11–$5.74 | 7.8× | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 6 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-07-30 | $1.10 | $1.21 | +10.0% |
| 2026-04-23 | $1.06 | $1.10 | +3.8% |
| 2026-01-29 | $0.84 | $0.89 | +6.0% |
| 2025-10-24 | $1.60 | $1.70 | +6.2% |
| 2025-07-31 | $0.96 | $0.90 | -6.2% |
| 2025-04-24 | $0.90 | $0.94 | +4.4% |
| 2025-01-30 | $0.71 | $0.70 | -1.4% |
| 2024-10-25 | $1.35 |
| $1.57 |
| +16.3% |
| $121.9B |
| — |
| GILDGilead Sciences, Inc. | $146.41 | +1.87% | $181.8B | — |
| GSKGSK plc | $50.05 | +4.00% | $100.3B | — |
Source: Financial Modeling Prep · peers by sector/industry
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.
@jenbunn @zuby34 @Jeremymartin007 @judgeyoung2 @ZY786 @ribbey @EBE_day @TraderRapp @Tradermikes40 @tonyctl $SNY SANOFI FOCUSING ON LATE STAGE TO COMMERCIAL DEALS FOR M&A - SANOFI CEO
View on StockTwits ↗
$TGTX Regarding seller AND buyer perspectives -- given the sheer volume of CURRENT AND FUTURE revenues on the line, I anticipate a COMPETITIVE buyout, and the players and proposals could be quite different. Examples: Perhaps $SNY submits an all-cash proposal, this could be quick with no anti-trust questions? $BIIB is financially capable of acquiring TGTX, but it cannot do so through a pure cash offer thus perhaps a structured acquisition of debt financing and stock-for-stock equity swaps more complicated but doable? Different tax paths or outcomes for TGTX’s current shareholders – but all good?
View on StockTwits ↗
$MNKD there's anecdotes then there's the reality of the findings of $UTHR Martine and the reality that afrezza has such coughing issues that it is has a black box warning label and terrible weekly scripts. Prandial insulin from $LLY and $NVO has no such Black Box Warning label and has been crushing afizzle since it was approved back in 2014 and dumped by $SNY more than a decade ago. afrezza dpi inhaled prandial insulin scripts for week ending 9/4/26 nrx 346 refills 492 ...
View on StockTwits ↗
H.C. Wainwright reiterated $CNTB Buy-$7 and said -- We recently hosted a KOL discussion ahead of Connect Biopharma's upcoming Seabreeze STAT asthma and COPD readouts and came away incrementally more positive on the setup. $SNY - REGN VRNA GSK AZN ABBV INSM LQDA H.C. Wainwright added—Most importantly, the KOL viewed treatment failure, including recurrent exacerbations and repeat acute-care utilization, as the most clinically meaningful measure of success, with approximately 30% relative reduction representing a meaningful win, ~40% a strong outcome and ~50% an especially compelling result. FEV1 remains important, but in our view the discussion reinforces that Seabreeze should be assessed primarily on whether rademikibart meaningfully reduces treatment failure over 28 days as that is the key measure physicians care about in practice. We believe this provides a favorable framework heading into the catalyst and remain positive on CNTB shares.
View on StockTwits ↗
Wall St is expecting 1.60 EPS for $SNY Q3 [Reporting 10/30 BMO] http://www.estimize.com/intro/sny?chart=historical&metric_name=eps&utm_cont
View on StockTwits ↗
@omega42 @MrBean1234 $SPRY’s neffy is already an FDA-approved, commercial epinephrine product. $AQST’s Anaphylm is not. SPRY also has significant pipeline optionality: its intranasal epinephrine platform is in a Phase 2b study for acute flares of chronic spontaneous urticaria (CSU), with interim data expected in Q1 2027. There is currently no FDA-approved on-demand treatment for acute CSU flares. SPRY also brought in a new CEO and CCO with extensive commercial experience, including years working together at Dynavax $SNY and major pharma company including $MRK. Most importantly, management continues to reiterate a path to cash-flow breakeven by the end of 2027 while aggressively cutting expenses and growing neffy adoption.
View on StockTwits ↗
$NVAX HEB, CVS, Walgreens, and Walmart pharmacies offer the Nuvaxovid (Novavax) COVID-19 vaccine. $SNY
View on StockTwits ↗JPMorgan🏁 $DNTH Overweight-$135 and said -- DNTH is a clinical-stage biotech developing therapeutics for severe autoimmune diseases led by claseprubart, an active-C1s inhibitor, with an initial focus on complement-mediated neuromuscular disorders. $SNY $ARGX AZN UCBJY Here's what JPMorgan went on to say in its initiation report: https://x.com/Quantumup1/status/2098358983132058013?s=20
View on StockTwits ↗
$BIIB $CLNN $QNTM $RHHBY $SNY From the article: “Clene Inc. (NASDAQ: CLNN) shared results from new analyses examining clinical outcomes among CNM-Au8(R)-treated patients whose neurofilament light chain (“NfL”) biomarker levels declined or stabilized. These findings will be included in Clene’s planned New Drug Application (“NDA”) seeking accelerated approval and are intended to address the questions raised by the U.S. Food and Drug Administration (“FDA”) during a March 2026 Type C meeting. At that meeting, the FDA acknowledged that NfL, a recognized blood marker of nerve-cell injury, has established prognostic value in amyotrophic lateral sclerosis (“ALS”) and could potentially serve as a reasonably likely surrogate endpoint to support accelerated approval.”
View on StockTwits ↗$ALT Who is most likely to sign a deal with Altimmune? $SNY $MRK $NVO
View on StockTwits ↗
A Micro-Cap Biotech Just Cleared a Milestone Most Never Reach $QNTM $SNY $RHHBY $BIIB $CLNN https://ibn.fm/MrHnd
View on StockTwits ↗
@Docdavid. Why are you misleading people? @Coopcoop posted that and tagged $SNY. Sanofi didn’t post it themselves as your post leads folks to believe. Seems very disingenuous to me.
View on StockTwits ↗$NVAX 🚨New publication: Vaccine Volume 92, 24 October 2026, 129034: “The platform trial in COVID-19 priming and BOOsting (PICOBOO): The reactogenicity of nine licensed COVID-19 vaccines delivered in immunocompetent adults”. 🟡 One of the key findings: Reactogenicity was consistently lowest after Nuvaxovid compared to mRNA vaccines. $SNY $PFE $MRNA https://www.sciencedirect.com/science/article/abs/pii/S0264410X26008431?via%3Dihub
View on StockTwits ↗
Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.